Skip to main content

Advertisement

SpringerLink
Log in

New developments in the diagnosis and treatment of irritable bowel syndrome

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Irritable bowel syndrome (IBS) is a common disorder with major health status and economic effects. Symptom criteria are of paramount importance in diagnosis, but differences among the Manning, Rome I, and Rome II criteria may lead to variable identification of people with the disorder. Practice guidelines are based on evidence and, to a greater degree, on consensus; therefore, experts vary on the specifics of ordering particular diagnostic tests. There is an overlap of IBS symptoms with those of celiac sprue, and selected patients should be tested for the latter disease. Symptom confusion with biliary pain and overlap with chronic pelvic pain could contribute to the predisposition of IBS patients to undergo cholecystectomy and hysterectomy. Development and documentation of effective therapy has been difficult, but depending on the selection of subgroups, there is evidence for usefulness of smooth muscle relaxants, loperamide, and antidepressants. Various forms of psychological therapy and new serotoninmodulating agents seem especially promising. The placebo effect of the physician-patient relationship has important therapeutic benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. The Burden of Gastrointestinal Diseases. Bethesda, MD: American Gastroenterological Association; 2001.

  2. Levy RL, Von Korff M, Whitehead WE, et al.: Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001, 96:3122–3129. Comprehensive study of the medical costs for IBS patients, which were similar to those for GERD patients. The majority of costs were not related to lower intestinal problems.

    Article  PubMed  CAS  Google Scholar 

  3. Whitehead WE, Palsson O, Jones KR: Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002, 122:1140–1156. Review of comorbid disorders, including shared pathophysiologic mechanisms, overlap with other somatic disorders, and a suggested model to explain the comorbidity.

    Article  PubMed  Google Scholar 

  4. Creed F, Ratcliffe J, Fernandez L, et al.: Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med 2001, 134:860–868. Study of quality of life and costs for patients with IBS that is refractory to the usual treatment, including analyses of abdominal and psychological symptoms in relation to these measures.

    PubMed  CAS  Google Scholar 

  5. Camilleri M: Management of the irritable bowel syndrome. Gastroenterology 2001, 120:652–668.

    Article  PubMed  CAS  Google Scholar 

  6. Horwitz BJ, Fisher RS: The irritable bowel syndrome. N Engl J Med 2001, 44:1846–1850.

    Article  Google Scholar 

  7. Jones J, Boorman J, Cann P, et al.: British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 2000, 47(suppl II):1–19.

    Google Scholar 

  8. Boyce PM, Koloski NA, Talley NJ: Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice? Am J Gastroenterol 2000, 95:3176–3183.

    Article  PubMed  CAS  Google Scholar 

  9. Thompson WG, Irvine EJ, Pare P, et al.: Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 2002, 47:225–235.

    Article  PubMed  CAS  Google Scholar 

  10. Thompson WG, Hungin APS, Neri M, Holtmann G, et al.: The management of irritable bowel syndrome: a European primary and secondary care collaboration. Eur J Gastroenterol Hepatol 2001, 13:933–939.

    Article  PubMed  CAS  Google Scholar 

  11. Fass R, Longstreth GF, Pimental M, et al.: Evidence- and consensus-based practice guidelines for the diagnosis of irritable bowel syndrome. Arch Intern Med 2001, 161:2081–2088. Guidelines for diagnosis and treatment of IBS based on review of the validity of symptom criteria and consensus of experienced primary care physicians and gastroenterologists.

    Article  PubMed  CAS  Google Scholar 

  12. Suleiman S, Sonnenberg A: Cost-effectiveness of endoscopy in irritable bowel syndrome. Arch Intern Med 2001, 161:369–375.

    Article  PubMed  CAS  Google Scholar 

  13. Yawn BP, Locke GR, Lydick E, et al.: Diagnosis and care of irritable bowel syndrome in a community-based population. Am J Manag Care 2001, 7:585–592.

    PubMed  CAS  Google Scholar 

  14. Parker TJ, Woolner JT, Prevost AT, et al.: Irritable bowel sundrome: is the search for lactose intolerance justified? Eur J Gastroenterol Hepatol 2001, 13:219–225.

    Article  PubMed  CAS  Google Scholar 

  15. Sanders DS, Carter MJ, Hurlstone DP, et al.: Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet 2001, 358:1504–1508. In an evaluation of specialist referral IBS patients for celiac sprue using serologic tests and biopsies, sprue was more common in patients than in control subjects.

    Article  PubMed  CAS  Google Scholar 

  16. Wahnschaffe U, Ullrich R, Riecken EO, Schulzke JD: Celiac disease-like abnormalities in a subgroup of patients with irritable bowel syndrome. Gastroenterology 2001, 121:1329–1338. Evaluation of diarrhea-predominant IBS patients for genotype, serum and intestinal antibodies, and histologic changes suggesting latent or potential celiac sprue. Patients with these findings improved after dietary gluten restriction.

    Article  PubMed  CAS  Google Scholar 

  17. Drossman DA: Irritable bowel syndrome: how far do you go in the workup? Gastroenterology 2001, 121:1512–1515.

    Article  PubMed  CAS  Google Scholar 

  18. Kennedy TM, Jones RH: Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population. Br J Surgery 2000, 87:1658–1663.

    Article  CAS  Google Scholar 

  19. Kennedy TM, Jones RH: The epidemiology of hysterectomy and irritable bowel syndrome in a UK population. Int J Clin Pract 2000, 54:647–650.

    PubMed  CAS  Google Scholar 

  20. Zondervan KT, Yudkin PL, Vessey MP, et al.: Chronic pelvic pain in the community: symptoms, investigations, and diagnoses. Am J Obstet Gynecol 2001, 184:1149–1155.

    Article  PubMed  CAS  Google Scholar 

  21. Bertram S, Kurland M, Lydick E, et al.: The patient’s perspective of irritable bowel syndrome. J Fam Pract 2001, 50:521–525.

    PubMed  CAS  Google Scholar 

  22. Gonsalkorale WM, Houghton LA, Whorwell PJ: Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness. Am J Gastroenterol 2002, 97:954–961.

    Article  PubMed  Google Scholar 

  23. Heymann-Mönnikes I, Arnold R, Florin I, et al.: The combination of medical treatment plus multicomponent behavioral therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome. Am J Gastroenterol 2000, 95:981–994.

    PubMed  Google Scholar 

  24. Jailwala J, Imperiale TF, Kroenke K: Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000, 133:136–147. Systematic review found that smooth muscle relaxants benefit abdominal pain, loperamide helps diarrhea, bulking agents are not clearly useful, and antidepressants are of questionable effectiveness.

    PubMed  CAS  Google Scholar 

  25. Akehurst R, Kaltenthaler E: Treatment of irritable bowel syndrome: a review of randomized controlled trials. Gut 2001, 48:272–282.

    Article  PubMed  CAS  Google Scholar 

  26. Jackson JL, O’Malley PG, Tomkins G, et al.: Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000, 108:65–72. Meta-analysis concluded that one of every three patients treated with antidepressants should improve, especially in severity of pain.

    Article  PubMed  CAS  Google Scholar 

  27. Kamm MA: The complexity of drug development for irritable bowel syndrome. Aliment Pharmacol Ther 2002, 16:343–351.

    Article  PubMed  CAS  Google Scholar 

  28. Longstreth GF, Hawkey CJ, Mayer EA, et al.: Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials. Aliment Pharmacol Ther 2001, 15:959–964.

    Article  PubMed  CAS  Google Scholar 

  29. Horton R: Lotronex and the FDA: a fatal eroison of integrity. Lancet 2001, 357:1544–1545.

    Article  PubMed  CAS  Google Scholar 

  30. Talley NJ: Serotoninergic neuroenteric modulators. Lancet 2001, 358:2061–2068. Concise review of pathophysiology of IBS and the thrapeutic potential of specific serotonin modulators.

    Article  PubMed  CAS  Google Scholar 

  31. Camilleri M, Northcutt AR, Kong S, et al.: Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomized, placebo-controlled trial. Lancet 2000, 355:1035–1040.

    Article  PubMed  CAS  Google Scholar 

  32. Friedel D, Thomas R, Fisher RS: Ischemic colitis during treatment with alosetron. Gastroenterology 2001, 120:557–560.

    Article  PubMed  CAS  Google Scholar 

  33. Camilleri M: Tegaserod. Aliment Pharmacol Ther 2001, 15:277–289.

    Article  PubMed  CAS  Google Scholar 

  34. Müller-Lisner SA, Fumagalli I, Bardhan, et al.: Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001, 15:1655–1666. Tegaserod caused rapid and sustained relief of abdominal pain and constipation and was well tolerated in this study.

    Article  Google Scholar 

  35. Pimental M, Chow EJ, Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95:3503–3506.

    Article  Google Scholar 

  36. Maxwell PR, Rink E, Kumar D, Mendall MA: Antibiotics increase functional abdominal symptoms. Am J Gastroenterol 2002, 97:104–108.

    Article  PubMed  CAS  Google Scholar 

  37. Hrobjartsson A, Gotzsche PC: Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001, 344:1594–1602.

    Article  PubMed  CAS  Google Scholar 

  38. Thompson WG: Placebos: a review of the placebo response. Am J Gastroenterol 2000, 95:1637–1643. Delightful commentary on the placebo effect.

    Article  PubMed  CAS  Google Scholar 

  39. Moerman DE, Jonas WB: Deconstructing the placebo effect and finding the meaning response. Ann Intern Med 2002, 136:471–476.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Kaiser Permanente Medical Care Program, 4647 Zion Avenue, 92120, San Diego, CA, USA

    George F. Longstreth MD

Authors
  1. George F. Longstreth MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Douglas A. Drossman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Longstreth, G.F., Drossman, D.A. New developments in the diagnosis and treatment of irritable bowel syndrome. Curr Gastroenterol Rep 4, 427–434 (2002). https://doi.org/10.1007/s11894-002-0014-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-002-0014-2

Keywords

Search

Navigation